The modulation of phosphatidylinositol biosynthesis in hamster hearts by methyl lidocaine.
Methyl lidocaine is an experimental anti-arrhythmic drug which has been shown to enhance the biosynthesis of phosphatidyl-inositol (PI) in the hamster heart. In this study, the effect of methyl lidocaine on enzymes involved in the biosynthesis of PI in the heart was examined. When the hamster heart was perfused with labelled methyl lidocaine, the majority of the compound was not metabolized after perfusion. The direct action of methyl lidocaine on an enzyme was studied by the presence of the drug in enzyme assays, whereas its indirect action was studied by assaying the enzyme activity in the heart after methyl lidocaine perfusion. CTP:phosphatidic acid cytidylyl-transferase, a rate-limiting enzyme in PI biosynthesis, was stimulated by methyl lidocaine in a direct manner. Kinetic studies revealed that methyl lidocaine caused a change in the affinity between the enzyme and phosphatidic acid and resulted in the enhancement of the reaction. Alternatively, acyl-CoA:lysophosphatidic acid acyltransferase, another key enzyme for PI biosynthesis, was not activated by the presence of methyl lidocaine. However, the enzyme activity was stimulated in hearts perfused with methyl lidocaine. The enhancement of the acyl-transferase by methyl lidocaine perfusion was found to be mediated via the adenylate cyclase cascade with the elevation of the cyclic AMP level. The stimulation of protein kinase A activity by cyclic AMP resulted in the phosphorylation and activation of the acyltransferase. Interestingly, the activity of protein kinase C was not stimulated by methyl lidocaine perfusion. We conclude that the enhancement of PI biosynthesis by methyl lidocaine in the hamster heart resulted from the direct activation of the cytidylyltransferase, as well as the phosphorylation and subsequent activation of the acyltransferase.
Lee
E
E
Department of Biochemistry and Molecular Biology and Pharmacology, Faculty of Medicine, University of Manitoba, Winnipeg, Canada.
Tardi
P G
PG
Man
R Y
RY
Choy
P C
PC
D000217:Acyltransferases / Q000378:metabolism; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D003994:Bucladesine / Q000494:pharmacology; D006224:Cricetinae; D000242:Cyclic AMP / Q000378:metabolism; D017868:Cyclic AMP-Dependent Protein Kinases / Q000378:metabolism; D004789:Enzyme Activation; D006321:Heart / Q000187:drug effects*; D008012:Lidocaine / Q000031:analogs & derivatives* / Q000494:pharmacology; D008647:Mesocricetus; D009206:Myocardium / Q000201:enzymology / Q000378:metabolism*; D010716:Phosphatidylinositols / Q000096:biosynthesis*; D011493:Protein Kinase C / Q000378:metabolism
D000889:Anti-Arrhythmia Agents; D010716:Phosphatidylinositols; C014672:N-methyllidocaine; D003994:Bucladesine; D008012:Lidocaine; D000242:Cyclic AMP; D000217:Acyltransferases; C018764:2-acylglycerophosphate acyltransferase; D017868:Cyclic AMP-Dependent Protein Kinases; D011493:Protein Kinase C